Hepatokines mediate NAFLD impact on metabolic diseases and help to identify subtypesGerman researchers from the University of Tübingen, Helmholtz Munich and the German Center for Diabetes Research, and Harvard Medical...
Antibody candidate for treating serious liver diseaseA study led by researchers from Karolinska Institutet has identified a drug candidate for the treatment of fatty liver. The preclinical...
Plenity induced weight loss results in NALFD fibrosis score improvementA post-hoc analysis showed that treatment for weight management with Plenity decreased a marker for liver fibrosis (the NAFLD fibrosis...